# Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection

> **NCT02023112** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 171 (actual)

## Conditions studied

- Hepatitis C Virus

## Interventions

- **DRUG:** ABT-450/r/ABT-267
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT02023112
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2015-04
- **Final completion:** 2015-09
- **Target enrollment:** 171 (ACTUAL)
- **Last updated:** 2021-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02023112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02023112, "Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02023112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*